

3年間の研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
森 友久			生体毒性情報学 第2版	京都 廣川書店	京都	2023	1-238

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki T, Hasegawa S, Koretaka Y, Mishima H, Tanaka H, Kagaya H.	A questionnaire-based study on the “Dame. Zettai. (Never. Ever.)” drug abuse prevention campaign and the medical use of narcotic agents	Jpn J Pharm Palliat Care Sci	15	121-128	2022
鈴木 勉	【別冊秋号オピオイド】(PART2)基礎編 オピオイド身体依存のメカニズム	LiSA 別冊	29別冊	165-168	2022
鈴木勉、加藤英明、船田正彦	日本における薬物の乱用、依存の現状と問題点	ペインクリニック	45(8)	839-846	2024
船田正彦	危険ドラッグの依存性	精神科	41	239-247	2022

船田正彦	海外の大麻規制変遷から考える国内の大麻規制再構築の意義	医薬品医療機器レギュラトリーサイエンス	54	36-42.	2023
Mori T, Uzawa N, Masukawa D, Hirayama S, Iwase Y, Hokazono M, Udagawa Y, Suzuki T.	Enhancement of the rewarding effects of 3,4-methylenedioxymethamphetamine in orexin knockout mice	Behav Brain Res	396	112802	2021
Sato D, Hamada Y, Narita M, Mori T, Tezuka H, Suda Y, Tanaka T, Yoshida S, Tamura H, Yamanaka A, Senba E, Kuzumaki N, Narita M.	Tumor suppression and improvement in immune systems by specific activation of dopamine D1-receptor-expressing neurons in the nucleus accumbens	Molecular Brain	15	17	2022
Mori T, Yamashita K, Takahashi K, Mano S, Sato D, Narita M	Characterization of the discriminative stimulus effect of quinpirole: Further evidence for functional interaction between central dopamine D ₁ /D ₂ -receptors	Pharmacol Biochem Behav	213	173314	2022
Mori T, Takemura Y, Arima T, Iwase Y, Narita M, Miyano K, Hamada Y, Suda Y, Matsuzawa A, Sugita K, Matsumura S, Sasaki S, Yamauchi T, Higashiyama K, Uezono Y, Yamazaki M, Kuzumaki N, Narita M.	Further investigation of the rapid-onset and short-duration action of the G protein-biased μ -ligand oliceridine	Biochem Biophys Res Commun	534	988-994	2021

Yoshida S, Hamada Y, Narita M, Sato D, Tanaka K, <u>Mori T</u> , Tezuka H, Suda Y, Tamura H, Aoki K, Kuzumaki N, Narita M.	Elucidation of the mechanisms underlying tumor aggravation by the activation of stress-related neurons in the paraventricular nucleus of the hypothalamus.	Molecular Brain	16	18	2023
Moriya S, Yoneta Y, Kuwata K, Imamura Y, Demizu Y, <u>Kurihara M</u> , Kittaka A, Sugiyama T.	PreQ1 Facilitates DNA Strand Invasion by PNA	Peptide Science 2021	2022	111-112	2022
Ichimaru Y, Kato K, Kurihara M, Jin W, Koike T, Kurosaki H.	Bis(nitrato- κ O)(1,4,8,11-tetra-aza-cyclo-tetra-decane- κ 4 N)zinc(II) methanol monosolvate.	IUCrdata	7(Pt 8)	x220854.	2022
Yuyama M, Misawa T, Demizu Y, Kanaya T, <u>Kurihara M</u> .	Design and synthesis of novel estrogen receptor antagonists with acetal containing biphenylmethane skeleton	Results in Chemistry	3	100124	2021
Moriya S, Shibasaki H, Kohara M, Kuwata K, Imamura Y, Demizu Y, <u>Kurihara M</u> , Kittaka A, Sugiyama T.	Synthesis and characterization of PNA oligomers containing preQ1 as a positively charged guanine analogue	Bioorg Med Chem Lett	39	127850	2021
Tomita K., Kuwahara Y., Igarashi K., <u>Kitanaka J.</u> , Kitanaka N., Takashi Y., Tanaka K., Roudkenar, M.H., Roushandeh A.M., Kurimasa A., Nishitani Y. & Sato T.	Therapeutic potential for KCC2-targeted neurological diseases.	Jpn. Dent. Sci. Rev.	59	431-438	2023

Kitanaka J., Kitanaka N., Tomita K., Hall S.F., Igarashi K., Uhl G.R. & Sato T.	Glycogen synthase kinase-3 inhibitors block morphine-induced locomotor activation, Straub tail, and depression of rearing in mice via a possible central action.	Neurochem.	48(7)	2230-2240	2023
Tomita K., Oohara Y., Igarashi K., <u>Kitanaka J.</u> , Kitanaka N., Tanaka K., Roudkenar, M.H., Roushandeh, A.M., Sugimura, M. & Sato, T.	Kamishoyosan and Kamikihito protect against decreased KCC2 expression via neuroinflammation induced by the P. gingivalis lipopolysaccharide treatment in PC-12 cells and improve behavioral abnormalities in male mice.	Heliyon	9(12)	e22784	2023
Oka M., Yoshino R., Kitanaka N., Hall F.S., Uhl G.R. & <u>Kitanaka J.</u>	Role of Glycogen Synthase Kinase-3 β in Dependence and Abuse Liability of Alcohol.	Alcohol Alcohol.	59(2)	agad086	2024
Kitanaka N., Arai K., Takehara K., Hall F.S., Tomita K., Igarashi K., Sato T., Uhl G.R. & <u>Kitanaka J.</u>	Opioid receptor antagonists reduce motivated wheel running behavior in mice.	Behav. Pharmacol.	35(2/3)	114-121	2024
Kobayashi C., Kitanaka N., Nakai M., Hall F.S., Tomita K., Igarashi K., Sato T., Uhl G.R. & <u>Kitanaka J.</u>	Protein phosphatase 2A inhibitors: A possible pharmacotherapy for benzodiazepine dependence	J. Pharm. Pharmacol.		10.1093/jp/p/rgae136	2024

<u>Masukawa D</u> (corresponding author), Takahagi R, Nakao Y, Goshima Y.	L-DOPA Receptor GPR143 Functionally Couples with Adrenergic α 1B Receptor at the Second Transmembrane Interface.	Biol Pharm Bull.	46	869-873	2023
Uchimura H, Kanai K, Arai M, Inoue M, Hishimoto A, <u>Masukawa D</u> (corresponding author), Goshima Y.	Involvement of the L- DOPA receptor GPR143 in acute and chronic actions of methylphenidate.	J Pharmacol Sci.	152	178-181	2023
Arai M, Suzuki E, Kitamura S, Otaki M, Kanai K, Yamasaki M, Watanabe M, Kambe Y, Murata K, Takada Y, Arisawa T, Kobayashi K, Tajika R, Miyazaki T, Yamaguchi M, Lazarus M, Hayashi Y, Itohara S, de Kerchove d'Exaerde A, Nawa H, Kim R, Bito H, Momiyama T, <u>Masukawa D</u> (corresponding author), Goshima Y.	Enhancement of haloperidol-induced catalepsy by GPR143, an L-DOPA receptor, in striatal cholinergic interneurons.	J Neurosci.	44(11)	e15042320 24.	2024
Inoue M, <u>Masukawa D</u> , Goshima Y	l-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells.	J Pharmacol Sci	156(1)	45-48	2024

Tajika R, <u>Masukawa D</u> , Arai M, Nawa H, Goshima Y	Opposite regulation by L -DOPA receptor GPR143 of the long and short f orms of the dopamine D 2 receptors.	J Pharmacol Sci	156(2)	77-81	2024